세계의 항비만 치료제 시장 : 치료 유형별, 최종 용도별 - 예측(2025-2030년)

The Anti-Obesity Therapeutics Market was valued at USD 9.98 billion in 2023, expected to reach USD 10.81 billion in 2024, and is projected to grow at a CAGR of 8.44%, to USD 17.60 billion by 2030.

The scope of the anti-obesity therapeutics market involves developing, producing, and marketing drugs and treatments that address obesity and related conditions. This industry is defined by a growing need to combat the global obesity epidemic, driven by rising obesity rates and associated health complications such as diabetes, cardiovascular diseases, and certain cancers. The necessity for anti-obesity therapeutics stems from heightened awareness of obesity's health effects, increased healthcare costs, and public health initiatives targeting weight management. Its application includes pharmaceuticals, dietary supplements, and lifestyle interventions, with end-users ranging from healthcare providers and fitness centers to individual consumers seeking weight loss solutions. Key growth factors influencing this market include technological advancements in drug development, government incentives for healthcare innovation, and increased investment in research and development. Additionally, the market is buoyed by a surge in biotechnology advancements and growing consumer acceptance of pharmaceutical interventions for weight management.

Potential opportunities arise from the increasing prevalence of obesity worldwide, driving demand for more effective and safer treatments. Companies can capitalize on these opportunities by developing novel therapeutics and personalized medicine approaches tailored to specific genetic profiles. However, the market faces limitations and challenges, such as stringent regulatory requirements, high R&D costs, and potential side effects associated with anti-obesity drugs, which hinder broader adoption. Innovation areas include exploring natural ingredients with weight management benefits, investigating the role of gut microbiome in obesity, and advancing combination therapies to enhance efficacy and reduce side effects. As the market evolves, businesses can benefit from expanding into emerging markets experiencing demographic and lifestyle changes driving obesity rates. In this competitive landscape, collaborations and partnerships with research institutions and healthcare providers are crucial to overcoming challenges and fostering innovation. Insights into market trends and consumer behavior will enable companies to navigate this dynamic sector effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Obesity Therapeutics Market

The Anti-Obesity Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incidences of obesity and related disorder
  • Rising adoption of sedentary lifestyle due to lack of exercise
  • Introduction of novel anti-obesity drugs
• Market Restraints
  • Risk of side effects of anti-obesity therapeutics such as psychiatric disorder as well as strokes
• Market Opportunities
  • Ongoing clinical trials and research & development activities
  • Increasing number of drug targets associated with clinically significant weight loss
• Market Challenges
  • Limited of knowledge regarding weight management

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Obesity Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Obesity Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Obesity Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Obesity Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Obesity Therapeutics Market

A detailed market share analysis in the Anti-Obesity Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Obesity Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Obesity Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Obesity Therapeutics Market

A strategic analysis of the Anti-Obesity Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Obesity Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Currax Pharmaceuticals LLC, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Merck & Co., Inc., Norgine B.V., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals, Inc., SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, and Vivus LLC.

Market Segmentation & Coverage

This research report categorizes the Anti-Obesity Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment Type, market is studied across Medications and Treatments. The Medications is further studied across Bupropion-naltrexone, Liraglutide, Orlistat, Phentermine-topiramate, and Semaglutide. The Treatments is further studied across Adjustable Gastric Banding, Endoscopic Sleeve Gastroplasty, and Gastric Bypass Surgery.
• Based on End-use, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidences of obesity and related disorder
    • 5.1.1.2. Rising adoption of sedentary lifestyle due to lack of exercise
    • 5.1.1.3. Introduction of novel anti-obesity drugs
  • 5.1.2. Restraints
    • 5.1.2.1. Risk of side effects of anti-obesity therapeutics such as psychiatric disorder as well as strokes
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing clinical trials and research & development activities
    • 5.1.3.2. Increasing number of drug targets associated with clinically significant weight loss
  • 5.1.4. Challenges
    • 5.1.4.1. Limited of knowledge regarding weight management
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Anti-Obesity Therapeutics Market, by Treatment Type

• 6.1. Introduction
• 6.2. Medications
  • 6.2.1. Bupropion-naltrexone
  • 6.2.2. Liraglutide
  • 6.2.3. Orlistat
  • 6.2.4. Phentermine-topiramate
  • 6.2.5. Semaglutide
• 6.3. Treatments
  • 6.3.1. Adjustable Gastric Banding
  • 6.3.2. Endoscopic Sleeve Gastroplasty
  • 6.3.3. Gastric Bypass Surgery

7. Anti-Obesity Therapeutics Market, by End-use

• 7.1. Introduction
• 7.2. Ambulatory Surgical Centers
• 7.3. Hospitals
• 7.4. Specialty Clinics

8. Americas Anti-Obesity Therapeutics Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Anti-Obesity Therapeutics Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Anti-Obesity Therapeutics Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Boehringer Ingelheim International GmbH
• 2. Bristol-Myers Squibb Company
• 3. Currax Pharmaceuticals LLC
• 4. Eisai Co., Ltd.
• 5. Eli Lilly and Company
• 6. F. Hoffmann-La Roche Ltd.
• 7. GlaxoSmithKline PLC
• 8. Merck & Co., Inc.
• 9. Norgine B.V.
• 10. Novartis AG
• 11. Novo Nordisk A/S
• 12. Pfizer Inc.
• 13. Rhythm Pharmaceuticals, Inc.
• 14. SHIONOGI & Co., Ltd.
• 15. Takeda Pharmaceutical Company Limited
• 16. Vivus LLC